Literature DB >> 3896238

Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

K Kato, T Yamada, K Kawahara, H Onda, T Asano, H Sugino, A Kakinuma.   

Abstract

Recombinant human interleukin-2 (rIL-2) produced in Escherichia coli was purified to apparent homogeneity by cation exchange chromatography and reverse phase high performance liquid chromatography. The amino acid composition, amino terminal amino acid sequence, and carboxyl terminal amino acid were consistent with those deduced from the cDNA sequence. Besides the molecular species with the amino terminal Ala, the purified preparation contained another species having an additional Met residue at the amino terminus corresponding to the initiation codon AUG. The molar absorption coefficient of rIL-2 was determined to be 9.58 X 10(3) M-1 cm-1 at 280nm in water. Ultracentrifugal analyses revealed that it existed as a monomeric form in 0.1 M NaCl. The apparent sedimentation coefficient (S20,w) was calculated to be 1.8 S.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896238     DOI: 10.1016/0006-291x(85)90472-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay.

Authors:  H Kanamaru; O Yoshida
Journal:  Urol Res       Date:  1989

2.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

3.  AK cells were developed from NK cells during in vitro culture of allogeneic or F1 anti-parental stimulation: functional conversion in recognizing H-2 expression of target cells accompanied by phenotypical conversion.

Authors:  K Taniguchi; Y I Kawano; K Nomoto
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

4.  Interleukin 2 receptor bearing T lymphocytes in patients with chronic liver disease.

Authors:  S Kakumu; K Yoshioka; A Fuji; H Tahara
Journal:  Gastroenterol Jpn       Date:  1988-08

5.  Purification and characterization of a high-molecular-weight form of recombinant human interleukin-2.

Authors:  Z Ahmad; D Ciolek; Y C Pan; H Michel; F R Khan
Journal:  J Protein Chem       Date:  1994-10

6.  Myasthenia gravis induces the activation and maturation of lymphocytes in thymoma.

Authors:  K Takahashi; Y Monden; S Saito; Y Kamamura; T Uyama
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

7.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

8.  Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2.

Authors:  M Katano; T Matsuo; T Morisaki; K Naito; F Nagumo; E Kubota; M Nakamura; T Hisatsugu; J Tadano
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

9.  Purification and renaturation of recombinant human interleukin-2.

Authors:  M P Weir; J Sparks
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

10.  Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

Authors:  S Hinuma; K Naruo; K Ootsu; T Houkan; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.